Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.77% | 10.53% | 9.99% | 8.63% | 10.04% |
| Total Other Revenue | -100.00% | -100.00% | 107.00% | -- | -- |
| Total Revenue | 10.48% | 10.23% | 10.08% | 8.90% | 10.33% |
| Cost of Revenue | 5.59% | 4.62% | 3.74% | 7.75% | 12.41% |
| Gross Profit | 14.86% | 15.30% | 16.02% | 9.92% | 8.53% |
| SG&A Expenses | 34.09% | 27.87% | 21.90% | 19.72% | 12.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.11% | 9.84% | 7.74% | 10.40% | 12.52% |
| Operating Income | 7.90% | 10.85% | 13.90% | 6.65% | 7.02% |
| Income Before Tax | 6.98% | 20.59% | 1,820.75% | 1,768.49% | 1,613.67% |
| Income Tax Expenses | 1.24% | 18.05% | 20.14% | -12.00% | 4.63% |
| Earnings from Continuing Operations | 8.18% | 21.10% | 538.70% | 838.09% | 865.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.18% | 21.10% | 538.70% | 838.09% | 865.96% |
| EBIT | 7.90% | 10.85% | 13.90% | 6.65% | 7.02% |
| EBITDA | 8.26% | 10.79% | 13.55% | 6.31% | 5.96% |
| EPS Basic | 9.37% | 22.53% | 546.48% | 848.27% | 872.78% |
| Normalized Basic EPS | 8.13% | 12.01% | 13.75% | 6.54% | 5.09% |
| EPS Diluted | 9.59% | 22.81% | 529.63% | 795.46% | 810.70% |
| Normalized Diluted EPS | 8.35% | 12.32% | 13.77% | 6.57% | 5.05% |
| Average Basic Shares Outstanding | -1.12% | -1.15% | -0.99% | -0.84% | -0.51% |
| Average Diluted Shares Outstanding | -1.32% | -1.41% | -0.98% | -0.83% | -0.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |